Piramal Buys Selected Pfizer OTCs To Pursue Market Leader Goal
This article was originally published in PharmAsia News
The consumer goods arm of Piramal Enterprises has just made its third acquisition in six months, keeping up a hectic deal-making pace in its quest to be one of India’s leading OTC players.
You may also be interested in...
Pfizer effects hundreds of field force job cuts in India as it rewires its commercialization approach and creates new roles leveraging its ‘digital core’, but industry experts suggest there is a complex mix of other factors at play as well.
French biotechs Servier and ILTOO sign an option agreement for the latter's IL-2 inhibitor for lupus, while Korean biotechs LegoChem and Bridge will team up in idiopathic pulmonary fibrosis.
For the last few years, Indian generic companies have been making headlines for all the wrong reasons, rapped by the US Food and Drug Administration over problems ranging from fudged test results to poor-quality manufacturing standards. But lately, the firms have been enjoying a run of good regulatory tidings, giving a fillip to their share prices.